Supernus Pharmaceuticals to acquire the central nervous system portfolio of the privately held biopharmaceutical company US WorldMeds for $530M.
"This acquisition aligns extremely well with our strategy of expanding and enhancing our commercial and late-stage assets and is a significant step in strengthening our leadership position in CNS. We expect this transaction to provide Supernus with enhanced operating cash flow, financial flexibility to execute on our strategy, and a continued strong balance sheet.”
Jack Khattar, President and CEO of Supernus.
Through this acquisition, Supernus will increase revenue by adding new commercial capabilities that are important for orphan drugs and specialty pharmacy products.